Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High-dose allopurinol for non-ST-segment elevation myocardial infarction
IRCT20191223045866N1Phase 3Completed
- Sponsor
- Isfahan University of Medical Sciences
- Start
- Sep 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Myocardial Infarction (MI) comparing Allopurinol with Placebo (2 arms). Primary endpoints: Inflammatory biomarkers and In-hospital cardiac-related complications. Started Sep 2019; status: completed.
02
Drugs
allopurinol
03
Conditions
Myocardial Infarction (MI)
Beyond the preview
Go deeper on IRCT20191223045866N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20191223045866N1.